Literature DB >> 26973072

Status of vaccine research and development of vaccines for dengue.

Kirsten S Vannice1, Anna Durbin2, Joachim Hombach3.   

Abstract

This review on the dengue vaccine pipeline was a solicited article and drafted based on the pre-defined template for PD-VAC.
Copyright © 2016 World Health Organization. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Clinical pipeline; Dengue vaccine; Vaccine development

Mesh：

Substances：

Year:  2016        PMID： 26973072     DOI： 10.1016/j.vaccine.2015.12.073

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  39 in total

Review 1.  Using Wolbachia for Dengue Control: Insights from Modelling.

Authors:  Ilaria Dorigatti; Clare McCormack; Gemma Nedjati-Gilani; Neil M Ferguson
Journal:  Trends Parasitol       Date:  2017-11-25

2.  An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.

Authors:  Akane Urakami; Mya Myat Ngwe Tun; Meng Ling Moi; Atsuko Sakurai; Momoko Ishikawa; Sachiko Kuno; Ryuji Ueno; Kouichi Morita; Wataru Akahata
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

3.  Using a Virion Assembly-Defective Dengue Virus as a Vaccine Approach.

Authors:  Chao Shan; Xuping Xie; Jing Zou; Roland Züst; Bo Zhang; Rebecca Ambrose; Jason Mackenzie; Katja Fink; Pei-Yong Shi
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

4.  Human CD4+ T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity.

Authors:  Michael A Angelo; Alba Grifoni; Patrick H O'Rourke; John Sidney; Sinu Paul; Bjoern Peters; Aruna D de Silva; Elizabeth Phillips; Simon Mallal; Sean A Diehl; Beth D Kirkpatrick; Stephen S Whitehead; Anna P Durbin; Alessandro Sette; Daniela Weiskopf
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

Review 5.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

Review 6.  Prospects for dengue vaccines for travelers.

Authors:  Sl-Ki Lim; Yong Seok Lee; Suk Namkung; Jacqueline K Lim; In-Kyu Yoon
Journal:  Clin Exp Vaccine Res       Date:  2016-07-29

7.  Hypothetical assessment of efficiency, willingness-to-accept and willingness-to-pay for dengue vaccine and treatment: a contingent valuation survey in Bangladesh.

Authors:  K M Ariful Kabir; Aya Hagishima; Jun Tanimoto
Journal:  Hum Vaccin Immunother       Date:  2020-08-21       Impact factor: 3.452

Review 8.  Complex immune correlates of protection in HIV-1 vaccine efficacy trials.

Authors:  Georgia D Tomaras; Stanley A Plotkin
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

9.  Structural basis of potent Zika-dengue virus antibody cross-neutralization.

Authors:  Giovanna Barba-Spaeth; Wanwisa Dejnirattisai; Alexander Rouvinski; Marie-Christine Vaney; Iris Medits; Arvind Sharma; Etienne Simon-Lorière; Anavaj Sakuntabhai; Van-Mai Cao-Lormeau; Ahmed Haouz; Patrick England; Karin Stiasny; Juthathip Mongkolsapaya; Franz X Heinz; Gavin R Screaton; Félix A Rey
Journal:  Nature       Date:  2016-06-23       Impact factor: 49.962

10.  Immune correlates of protection for dengue: State of the art and research agenda.

Authors:  Leah C Katzelnick; Eva Harris
Journal:  Vaccine       Date:  2017-07-28       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.